Docetaxel is the first-line chemotherapy and the only approved chemotherapy for men with metastatic castrate resistant prostate cancer (CRPC). We all know that Docetaxel will stop working, so what do you do when this happens? […]
A study by Yu et al., of men with a rising PSA after failed radical prostatectomy or radiation therapy who were placed on intermittent androgen deprivation therapy (IADT) indicated that the length of their first “off cycle” correlates with their expected time to developing castrate resistant prostate cancer (CRPC) and to their prostate cancer-specific mortality. [...]
More from my explorations at the American Association of Cancer Researchers (AACR) conference in Washington, D.C. Abstract 5386 described a study using a thalidomide analogue called lenalidomide (Revlimid), in combination with Taxotere, which currently is the only approved drug for chemotherapy for advanced, metastatic castrate resistant prostate cancer. […]
There were many themes running through the recent American Association of Cancer Researchers (AACR) conference that I just attended in Washington D.C. One significant theme running through the conference was the need to develop personalized medicine to be able to successfully control cancer. This leads us to the question, What is personalized medicine? [...]
I am in Washington at the AACR conference so my blog posts might be irregular until next Thursday or Friday. I will try and share any interesting or important things I see or learn while at the conference. Joel T Nowak, MA, MSW